Company Overview and News

 
KL shares open lower on technical correction

2018-10-18 malaymail
KUALA LUMPUR, Oct 18 — Bursa Malaysia opened lower today on a technical correction and amid concerns over rising US interest rates and global trade tensions.
PBLOF 0026 1295 BSMAF 1818 7079

 
Wall St rebound lifts Bursa at opening

2018-10-17 malaymail
KUALA LUMPUR, Oct 17 — Bursa Malaysia opened higher today, lifted by the overnight rebound on Wall Street, dealers said.
PBLOF 0026 1295 BSMAF 1818

 
Bursa continues firmer at mid-morning

2018-10-17 malaymail
KUALA LUMPUR, Oct 17 — Bursa Malaysia continued to trade higher at mid-morning today on bullish sentiment following a strong performance on Wall Street, dealers said.
0026 7036 BSMAF HIPEF 1818 5199

 
KLCI reverses loss, tracks modest regional gains

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF

 
Continued selling pushes down Bursa at opening

2018-10-16 malaymail
KUALA LUMPUR, Oct 16 — Bursa Malaysia opened lower today on continued selling momentum, while tracking the weaker performance of Wall Street.
PBLOF 0026 1295 BSMAF 7066 1818

 
KLCI pares loss, remains in red tracking regional markets

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF

 
Bursa opens easier in line with Asian markets

2018-10-08 malaymail
KUALA LUMPUR, Oct 8 — Bursa Malaysia extended its losses at the opening today in line with the weaker performance in regional markets, said a dealer.
PBLOF 5225 0026 5819 7036 1295 Q0F BSMAF IHHHF 1818

 
Bursa ends softer in sync with Asian peers

2018-10-04 malaymail
KUALA LUMPUR, Oct 4 — Bursa Malaysia finished lower today, tracking losses in Asian markets, despite the firmer performance in the overnight US stock market.
PBLOF 0026 1295 BSMAF 7123 1818

 
KLCI remains in the red, tracks regional slump

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at the midday break, in line with slump at most regional markets.
HLFBF 5183 PECGF 1082 BATS 4162 7765 5014 9334 7123 5199 4588 3026 0026 5219 MYPRY HIPEF

 
KLCI down 0.36% on sustained weaker sentiment

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at mid-morning today on sustained weaker sentiment at the domestic market.
7083 5183 5172 PECGF BATS 4162 5014 5199 4634 KLKBY 2445 5226 4456 5347 3026 0026 TNABY MYPRY 2836 TNABF HIPEF

 
Bursa ends higher on buying sentiment

2018-10-02 malaymail
KUALA LUMPUR, Oct 2 ― Bursa Malaysia was higher at today's closing on continued buying in selected heavyweights, namely Genting Malaysia, Genting Bhd and Nestle, which together contributed 2.39 points to the gains in the composite index.
GMALY PBLOF 4715 0026 GMALF 5819 1295 BSMAF HIPEF GEBHF 1818 5199

 
KLCI stays shy of 1,800 as regional markets retreat

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY

 
Bursa higher at mid-morning

2018-10-02 malaymail
KUALA LUMPUR, Oct 2 — Shares on Bursa Malaysia continued climbing into positive territory at mid-morning supported by buying in selected heavyweights.
0026 7108 BSMAF HIPEF 1818 5199

 
KLCI edges up but stays shy of 1,800 level

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI edged up at mid-morning today but stayed shy of the crucial 1,800-point level.
UPBMF BATS 4162 5168 2089 5256 5199 4456 3301 0026 7108 HIPEF 3719 HRGHY

 
FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...